Good MorningEquity markets advanced on Tuesday in hopes that stability in the trade outlook would soon emerge. With maximum uncertainty in the air, simply solidifying the outlook regardless of tariffs could be enough to catalyze a significant broad market stock rally. The index is in rebound mode and moving higher, with eyes on the 5,700 level. Moving above it would trigger the market, leading to a retest of the all-time high.
Economic data and earnings are other potential catalysts for stocks this week. The monthly labor data is due, and the first report, the JOLTs report, was weaker than expected but still shows ample job availability. Regarding earnings, reports from Microsoft, Meta Platforms, and Amazon will give a deep look into the state of tech spending, and it is expected to be strong. The question is whether they will outperform consensus estimates and provide positive guidance, and the odds are high they will due to the low bar set by analysts. Featured: $500 to “Partner” with Elon Musk? Shocking… (Ad) 
|
Stocks | | | Much like its wild month of April, a scary Wednesday for Wall Street found a gentler ending as U.S. stocks stormed back from steep early losses to continue their manic swings amid uncertainty about what President Donald Trump’s trade war will do to the economy.The S&P 500 rose 0.1% to extend it... Read the Full Story |
|
From Our Partners | | Something big is brewing in Washington.
According to my research, an executive order from President Trump could be just weeks away.
And it holds the potential to trigger one of the most explosive tech booms in US history.
At the center of it all? Robots.
Not the kind that clean your house or pour you coffee.
But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | | This little-known company holds nearly 100 patents and trades for around $7 |
|
Markets | | | American businesses are cancelling orders from China, postponing expansion plans and hunkering down to see what trade policy surprises President Donald Trump plans to spring on them next.The president’s massive and unpredictable taxes on imports seem likely to mean emptier shelves and higher prices ... Read the Full Story |
|
Markets | | |
It's said about the weather that if you give it a few minutes it will change. The same could be true about sentiment for CrowdStrike Holdings Inc. (NASDAQ: CRWD). The company is a month away from earnings, and the stock is behaving in a volatile fashion. At the beginning of April, CRWD stoc... Read the Full Story |
|
From Our Partners | | During last month’s historic market swings, most investors panicked. But a small group of traders calmly watched their accounts grow.
They were using Professor Jeff Bierman’s “Genesis Cog” system to spot stocks being hijacked by institutional algorithms—before the moves happened. | | See how they used this strategy to profit during extreme volatility. |
|
Markets | | |
With tariffs causing markets to waver in 2025, many investors were growing worried about the guidance companies would put out. Analysts expect certain stocks not to give guidance for the rest of the year due to the difficulty in forecasting amid the tariff policy environment.
Additionally, many s... Read the Full Story |
|
Markets | | | Higher tariffs on U.S. imports of products from China are taking a toll on the world's second-largest economy as export orders sink, according to monthly surveys of Chinese factory managers released Wednesday. The official survey by the China Federation of Logistics and Purchasing shows export order... Read the Full Story |
|
From Our Partners | | Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists | | [See The Details Here] |
|
Markets | | |
Coca-Cola’s (NYSE: KO) stock price can bubble to new highs this year because its Q1 results and guidance update show its everywhere-is-local approach to business and international growth agenda is working.
The company faces headwinds in 2025 like virtually every other S&P 500 business... Read the Full Story |
|
Markets | | | Europe’s economy grew more strongly in the first three months of the year, only to see hopes for an ongoing recovery quickly squelched by U.S. President Donald Trump’s trade war.Gross domestic product in the 20 eurozone countries grew 0.4% in the first quarter, improving on 0.2% growth in the last p... Read the Full Story |
|
Markets | | |
A late April 2025 rally in the S&P 500 has sparked a wave of investor optimism, with some asserting that the market has fully absorbed the effects of President Trump’s tariffs. However, this optimism may be premature.
Key indicators point to significant headwinds ahead. Entrenched inf... Read the Full Story |
|
Markets | | |
Domino’s Pizza (NASDAQ: DPZ) faces challenges and headwinds in 2025, but its results and guidance show that it can build leverage despite these obstacles. The Q1 results include system-wide growth and improved profitability, attributed to the Hungry for MORE strategy.
Guidance was reaffir... Read the Full Story |
|
Markets | | | In a visit Tuesday to Warren, Michigan, President Donald Trump celebrated his first 100 days back in office by touting his accomplishments, while embellishing some and misrepresenting others.The speech of about 90 minutes was reminiscent of a campaign rally and covered much of the same ground as he ... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
